<DrugInformationSummary id="CDR0000812508"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Epcoritamab-bysp works by bringing healthy T cells (immune cells that help kill cancer cells) and lymphoma cells close together so the T cells can more effectively kill the lymphoma cells. It does this by binding to a protein called CD3 on healthy T cells and a protein called CD20 on B cells (the immune cells that are cancerous in B-cell lymphomas). Epcoritamab-bysp is a type of targeted therapy drug called a bispecific T-cell engager (BiTE).</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/epcoritamab-bysp">Epcoritamab-bysp</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000798973">epcoritamab-bysp</TerminologyLink><GlossaryLink ref="CDR0000812500">epcoritamab</GlossaryLink><USBrandNames><USBrandName>Epkinly</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>EP-koh-RIH-tah-mab</TermPronunciation><MediaLink ref="CDR0000813039" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000813040" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Epcoritamab-bysp</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Epcoritamab-bysp
         is approved to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">Diffuse large B-cell lymphoma</GlossaryTermRef></Strong> (DLBCL) or <Strong><GlossaryTermRef href="CDR0000045710" dictionary="Cancer.gov" audience="Patient">high-grade</GlossaryTermRef> <GlossaryTermRef href="CDR0000444967" dictionary="Cancer.gov" audience="Patient">B-cell lymphoma</GlossaryTermRef>.</Strong></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">Follicular lymphoma</GlossaryTermRef>.</Strong></ListItem>
   </ItemizedList><Para id="_6">Epcoritamab-bysp is used in patients with cancer that has come back or did not get better after at least two lines of systemic therapy.</Para><Para id="_4">These uses are approved under FDAâ€™s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that epcoritamab-bysp provides a clinical benefit in these patients.</Para><Para id="_5">Epcoritamab-bysp
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Epcoritamab-bysp</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/798973">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.39">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a623023.html">Epcoritamab-bysp</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.40"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.41">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/large-b-cell-lymphoma-axi-cel-zuma-7-trial">Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C163022">Find Clinical Trials for Epcoritamab-bysp</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2023-06-30</DateFirstPublished><DateLastModified>2024-06-28</DateLastModified></DrugInformationSummary>
